1847394-95-9

1847394-95-9 structure
1847394-95-9 structure
  • Name: Setrusumab
  • Chemical Name: Setrusumab
  • CAS Number: 1847394-95-9
  • Molecular Formula:
  • Molecular Weight:
  • Catalog: Research Areas Cancer
  • Create Date: 2023-01-15 20:02:45
  • Modify Date: 2025-08-25 14:11:05
  • Setrusumab (BPS 804) is a fully humanized monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer[1].

Name Setrusumab
Description Setrusumab (BPS 804) is a fully humanized monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer[1].
Related Catalog
In Vivo Setrusumab (100 mg/kg;每周一次,静脉注射,持续 4 周) 抑制小鼠乳腺癌诱导的骨转移和肌肉无力[1]。 Animal Model: 8-week-old female immune-compromised CB-17/lcr-Prkdcscid/Rj mice with MDA-MB-231 breast cancer cells injection[1] Dosage: 100 mg/kg Administration: Intravenous injection; 100 mg/kg once a week for 4 weeks Result: Significantly inhibited tumor growth in bones and breast cancer cell dissemination into other organs. Inhibited breast cancer-induced osteolytic lesions and subsequent loss of bone mass of the distal femur and of the proximal tibia. Redued phosphorylation of IKKα, IKKβ, and p65.
References

[1]. Hesse E, et al. Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight. 2019 Apr 9;5(9):e125543.

No Any Chemical & Physical Properties
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.